---
title: "Cleo Diagnostics Hits Key U.S. Trial Milestone for Ovarian Cancer Test"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281095740.md"
description: "Cleo Diagnostics Hits Key U.S. Trial Milestone for Ovarian Cancer Test"
datetime: "2026-03-31T00:44:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281095740.md)
  - [en](https://longbridge.com/en/news/281095740.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281095740.md)
generator: "portal-rs"
---

# Cleo Diagnostics Hits Key U.S. Trial Milestone for Ovarian Cancer Test

Cleo Diagnostics Hits Key U.S. Trial Milestone for Ovarian Cancer Test

### Related Stocks

- [AXDX.US](https://longbridge.com/en/quote/AXDX.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [CLSDQ.US](https://longbridge.com/en/quote/CLSDQ.US.md)
- [CODX.US](https://longbridge.com/en/quote/CODX.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Co-Diagnostics Adjourns Annual Meeting, Sets New Date](https://longbridge.com/en/news/298047178.md)
- [Co-Diagnostics Launches Integrated Cloud and Mobile Infrastructure in India | CODX Stock News](https://longbridge.com/en/news/297919373.md)
- [Co-Diagnostics launches integrated cloud, mobile infrastructure in India](https://longbridge.com/en/news/297919002.md)
- [Koala trial doses first patient with novel KMA‑targeting CAR‑T](https://longbridge.com/en/news/298021066.md)
- [Grupa Azoty announces extraordinary shareholder meeting](https://longbridge.com/en/news/297635728.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**